Regulatory T cells (Treg) suppress autoreactive immune responses and limit the efficacy of tumor vaccines;however, it remains a challenge to selectively eliminate or inhibit Treg and other regulatory cells. In our recent studies supported by the current grant (1R01CA090427;7/2002-6/2007), we found that A20, a negative regulator of the TLR and TNFR signaling pathways, critically restricts the maturation, cytokine production, and immunostimulatory potency of dendritic cells (DC). A20-silenced DCs expressed enhanced levels of proinflammatory cytokines and costimulatory surface molecules. A20-silenced DCs had contrasting effects on T cell subsets, namely inhibiting Treg but hyperactivating CTLs and Th that were more refractory to Treg-mediated suppression, leading to enhanced antitumor immunity in mice. The results of this study provide a novel strategy to supersede Treg- mediated suppression in an antigen-specific manner. In this continuation study, we aim to develop more potent tumor vaccines capable of overcoming immune suppression. The central hypothesis of this continuation study is that inhibition of A20 and integrin av/?8 or neuropilin, which is required for TGF? activation, and stimulation with TLR5 agonist uniquely triggers and sustains TLR signaling cascades to endow DCs with the unique capacity to inhibit Treg and hyperactivate antitumor CTL/Th cells.
The specific aims are: 1. to test whether DCs that are transduced to coexpress the inhibitor of TLR's negative regulator A20 (shA20) and secretory flagellin (FliC), TLR5 ligand, to uniquely trigger and sustain TLR signaling cascades can efficiently stimulate the effector phase of antitumor memory responses to tip the balance from immunosuppression to antitumor immunity in tumor-bearing mice. 2. to test the hypothesis that silencing of integrin av/?8 or neuropilin (Nrp) 1 blocks the ability of DCs to activate latent TGF-?, reducing their ability to induce Foxp3 expression and convert conventional T cells into Treg cells. And 3. to test the hypotheses that murine and human DCs that coexpress FliC and shRNAs of both A20 and integrin av/?8 or Nrp1 induce potent antitumor responses capable of overcoming Treg suppression and have a unique ability to persistently stimulate adoptively transferred T cells for combinational immunotherapy. The significance of this study is twofold: first, this study may lead to the development of more potent tumor vaccines capable of overcoming immunosuppression with the potential of clinical applications;second, this study contributes to the basic understanding of molecular and cellular mechanisms that critically regulate antigen presentation, immunosuppression, and antitumor immunity.

Public Health Relevance

In this continuation study, we aim to develop more potent tumor vaccines capable of overcoming immune suppression. Specifically, we will test whether inhibition of the negative regulator A20 and stimulation with TLR agonists will allow dendrite cells to induce effective antitumor immunity, leading to more potent tumor immunotherapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA090427-09
Application #
8299617
Study Section
Cancer Immunopathology and Immunotherapy Study Section (CII)
Program Officer
Howcroft, Thomas K
Project Start
2001-01-01
Project End
2014-07-31
Budget Start
2012-08-01
Budget End
2013-07-31
Support Year
9
Fiscal Year
2012
Total Cost
$316,496
Indirect Cost
$121,128
Name
University of Southern California
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
072933393
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Chen, Ke-Zhong; Lou, Feng; Yang, Fan et al. (2016) Circulating Tumor DNA Detection in Early-Stage Non-Small Cell Lung Cancer Patients by Targeted Sequencing. Sci Rep 6:31985
Guo, Nannan; Lou, Feng; Ma, Yongfu et al. (2016) Circulating tumor DNA detection in lung cancer patients before and after surgery. Sci Rep 6:33519
Xu, Song; Lou, Feng; Wu, Yi et al. (2016) Circulating tumor DNA identified by targeted sequencing in advanced-stage non-small cell lung cancer patients. Cancer Lett 370:324-31
Liu, Suqin; Wang, Hongjiang; Zhang, Lizhi et al. (2015) Rapid detection of genetic mutations in individual breast cancer patients by next-generation DNA sequencing. Hum Genomics 9:2
Jiang, Xiao-Xia; Chou, YuChia; Jones, Lindsey et al. (2015) Epigenetic Regulation of Antibody Responses by the Histone H2A Deubiquitinase MYSM1. Sci Rep 5:13755
Bai, Jun; Gao, Jinglong; Mao, Zhijun et al. (2015) Genetic mutations in human rectal cancers detected by targeted sequencing. J Hum Genet 60:589-96
Feng, Hongxiang; Wang, Xiaowei; Zhang, Zhenrong et al. (2015) Identification of Genetic Mutations in Human Lung Cancer by Targeted Sequencing. Cancer Inform 14:83-93
Xu, Zhi; Huo, Xinying; Ye, Hua et al. (2014) Genetic mutation analysis of human gastric adenocarcinomas using ion torrent sequencing platform. PLoS One 9:e100442
Bai, Xusheng; Zhang, Enke; Ye, Hua et al. (2014) PIK3CA and TP53 gene mutations in human breast cancer tumors frequently detected by ion torrent DNA sequencing. PLoS One 9:e99306
Won, Haejung; Nandakumar, Vijayalakshmi; Yates, Peter et al. (2014) Epigenetic control of dendritic cell development and fate determination of common myeloid progenitor by Mysm1. Blood 124:2647-56

Showing the most recent 10 out of 34 publications